MedTrace Logo

A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma

NCT00911924 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2015-05-20

No results posted yet for this study

Summary

Prospective, unmasked, evaluation of the iStent in patients that have primary open-angle glaucoma (OAG). Stent implantation in one eye will be used for analysis, with medication added at 6 months, as required.

Conditions

  • Glaucoma
  • Eye Diseases
  • Glaucoma, Open-Angle

Interventions

DEVICE

iStent

Glaukos iStent, medication

Sponsors & Collaborators

  • Glaukos Corporation

    lead INDUSTRY

Principal Investigators

  • Jeff Wells, PharmD, MBA · Glaukos Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • Armenia
  • Austria
  • France
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00911924 on ClinicalTrials.gov